AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22540912 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus rosiglitazone (4 mg twice a day)
Number of subjects: 699
Study 22540912 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus lifestyle intervention
Number of subjects: 699
Study 19709100 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E ointment 10% (G(10%))
Number of subjects: 1005
Study 19709100 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E ointment 15% (G(15%))
Number of subjects: 1005
Study 19709100 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (G(Veh))
Number of subjects: 1005
Study 18802906 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR) with papillary muscle realignment
Number of subjects: 30
Study 18802906 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) only
Number of subjects: 30
Study 17240929 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening paint-on gel with polyethylene strip barrier
Number of subjects: 33
Study 17240929 — intervention group
Group type: COMPARATOR
Intervention: Whitening paint-on gel alone
Number of subjects: 33
Study 12419855 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0
Study 12419855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10987605 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BV pacing)
Number of subjects: 32
Study 10987605 — intervention group
Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 32
Study 10987605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pacing periods
Number of subjects: 32
Study 8970662 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 32
Study 8970662 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 32
Study 1333719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous yohimbine (0.4 mg/kg)
Number of subjects: 38
Study 1333719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (2 micrograms/kg)
Number of subjects: 38
Study 3881263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg/day (Trental 400 t.d.s.)
Number of subjects: 138
Study 3881263 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid and dipyridamole (ASAD, 1,050 mg + 150 mg/day)
Number of subjects: 138
Study 30531477 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06372865 2.5 mg twice daily
Number of subjects: 90
Study 30531477 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06372865 7.5 mg twice daily
Number of subjects: 90
Study 30531477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28270181 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel-epirubicin (PE) regimen
Number of subjects: 293
Study 28270181 — intervention group
Group type: COMPARATOR
Intervention: Tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide (FEC) regimen
Number of subjects: 293
Study 27498527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb peripheral nerve blocks with sedation or general anesthesia
Number of subjects: 60
Study 27498527 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 24901546 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-slice analysis
Number of subjects: 22
Study 24901546 — intervention group
Group type: COMPARATOR
Intervention: Whole kidney analysis
Number of subjects: 22
Study 23111035 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic simulator (n = 11)
Number of subjects: 31
Study 23111035 — intervention group
Group type: EXPERIMENTAL
Intervention: XBOX 360 gaming console (n = 10)
Number of subjects: 31
Study 23111035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo DS handheld gaming system (n = 10)
Number of subjects: 31
Study 23111035 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game play (more than 10 hours weekly)
Number of subjects: 31
Study 19730966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of granisetron 0.1 mg iv and promethazine 6.25 mg iv
Number of subjects: 100
Study 19730966 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 6.25 mg iv
Number of subjects: 100
Study 19730966 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 0.1 mg iv
Number of subjects: 100
Study 17972482 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting distracting visual transients repeatedly prior to the change
Number of subjects: 0
Study 17972482 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional filtering of distracting transient signals
Number of subjects: 0
Study 17972482 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of presenting transient signals
Number of subjects: 0
Study 15023195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention (NI)
Number of subjects: 54
Study 15023195 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 54
Study 11760633 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 day training seminar for nurse case managers
Number of subjects: 65
Study 9591489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) gonadotropins
Number of subjects: 71
Study 9591489 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) gonadotropins
Number of subjects: 71
Study 7873701 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent negative variation (CNV) to female slides
Number of subjects: 6
Study 7873701 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent negative variation (CNV) to male and female slides
Number of subjects: 6
Study 7873701 — intervention group
Group type: COMPARATOR
Intervention: Contingent negative variation (CNV) to adult female slides
Number of subjects: 6
Study 7873701 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent negative variation (CNV) to female adults and female children
Number of subjects: 6
Study 3348141 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of sustained-release isosorbide dinitrate (ISDN)
Number of subjects: 40
Study 3348141 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of sustained-release nifedipine
Number of subjects: 40
Study 31135099 — intervention group
Group type: EXPERIMENTAL
Intervention: Miliacin encapsulated within polar lipids (MePL)
Number of subjects: 65
Study 31135099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30017873 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized dry ivy leaf extract syrup along with regular nasal irrigation for five days after nasal packing removal
Number of subjects: 70
Study 30017873 — intervention group
Group type: COMPARATOR
Intervention: Nasal lavage only
Number of subjects: 70
Study 28223381 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg
Number of subjects: 0
Study 28223381 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,800 mg
Number of subjects: 0
Study 28223381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28223381 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study 25750540 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 796
Study 25750540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796
Study 24316325 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 201
Study 24316325 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) at intervention sites
Number of subjects: 201
Study 24316325 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) at observational sites
Number of subjects: 201
Study 22637938 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional rearing
Number of subjects: 114
Study 22637938 — intervention group
Group type: COMPARATOR
Intervention: Community control
Number of subjects: 114
Study 19572082 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete compression ultrasound (CCUS)
Number of subjects: 3871
Study 19572082 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding anticoagulant therapy after negative CCUS
Number of subjects: 3871
Study 17631801 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Dinggui Oil (DGO-H, 1.2 g, 3 times daily)
Number of subjects: 198
Study 17631801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Dinggui Oil (DGO-L, 0.8 g, 3 times daily)
Number of subjects: 198
Study 17631801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5.0 g, 3 times daily)
Number of subjects: 198
Study 14996420 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal lymphocyte (PL) immunotherapy
Number of subjects: 124
Study 14996420 — intervention group
Group type: COMPARATOR
Intervention: Autologous lymphocyte (AL) immunotherapy
Number of subjects: 124
Study 14996420 — intervention group
Group type: COMPARATOR
Intervention: Third party lymphocyte (TPL) immunotherapy
Number of subjects: 124
Study 14996420 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) control
Number of subjects: 124
Study 14996420 — intervention group
Group type: COMPARATOR
Intervention: Non-treated (NT) control group
Number of subjects: 124
Study 11575618 — intervention group
Group type: EXPERIMENTAL
Intervention: Caution to be realistic
Number of subjects: 124
Study 11575618 — intervention group
Group type: COMPARATOR
Intervention: Standard malingering indexes (Infrequency, F; Back Side, F, Fb; F-Correction, F-K; and Infrequency-Psychopathology, F(p))
Number of subjects: 124
Study 9703284 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2
Number of subjects: 60
Study 9703284 — intervention group
Group type: COMPARATOR
Intervention: IL‐2 with IFN‐alpha
Number of subjects: 60
Study 9410372 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone) 90 mg per day
Number of subjects: 283
Study 9410372 — intervention group
Group type: COMPARATOR
Intervention: Oral progesterone (Utrogestan) 300 mg per day
Number of subjects: 283
Study 9410372 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone)
Number of subjects: 283
Study 9410372 — intervention group
Group type: COMPARATOR
Intervention: Oral progesterone (Utrogestan)
Number of subjects: 283
Study 9410372 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety parameters for both groups
Number of subjects: 283
Study 2333843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phylloquinone diet (n = 11)
Number of subjects: 22
Study 2333843 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative fasting (n = 11)
Number of subjects: 22
Study 2333843 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (n = 7)
Number of subjects: 22
Study 2333843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phylloquinone diet after 3 days (n = 8)
Number of subjects: 22
Study 6785626 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation with lysozyme, papain and bacitracin
Number of subjects: 100
Study 6785626 — intervention group
Group type: COMPARATOR
Intervention: Comparative preparation with a disinfectant only
Number of subjects: 100
Study 31557351 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D Exchange Registry
Number of subjects: 51524
Study 31557351 — intervention group
Group type: COMPARATOR
Intervention: DPV Registry
Number of subjects: 51524
Study 31557351 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D Exchange Registry (injection users)
Number of subjects: 51524
Study 31557351 — intervention group
Group type: COMPARATOR
Intervention: DPV Registry (injection users)
Number of subjects: 51524
Study 31557351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Registries (minority status)
Number of subjects: 51524
Study 31156048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Gradient (IG)
Number of subjects: 145
Study 31156048 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Acceleration (AvAcc)
Number of subjects: 145
Study 28049170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 µg twice daily) for 6 months
Number of subjects: 114
Study 28049170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 µg twice daily) for 30 months
Number of subjects: 114
Study 28049170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (500/50 µg twice daily) for 30 months
Number of subjects: 114
Study 28049170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 26482071 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 60
Study 26482071 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 25863853 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma group (31 patients using at least 1 topical IOP-lowering medication)
Number of subjects: 61
Study 25863853 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 patients with no diagnosis of glaucoma or history of topical therapy usage)
Number of subjects: 61
Study 25863853 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma group
Number of subjects: 61
Study 25863853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 23419875 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 90
Study 23419875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23419875 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 90
Study 21485550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanometer silver dressing
Number of subjects: 60
Study 21485550 — intervention group
Group type: COMPARATOR
Intervention: Vaseline dressing
Number of subjects: 60
Study 18616708 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily
Number of subjects: 88
Study 18616708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 17053357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration of physical or sexual violence against female partners
Number of subjects: 1275
Study 17053357 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe perpetration of violence (both physical and sexual)
Number of subjects: 1275
Study 17053357 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perpetration of intimate partner violence
Number of subjects: 1275
Study 12611785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy in addition to antidepressants and clinical management
Number of subjects: 158
Study 12611785 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants and clinical management alone
Number of subjects: 158
Study 12611785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 158
Study 11004617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifetroban
Number of subjects: 165
Study 11004617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 9821994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track cardiac anesthetic regimen
Number of subjects: 617
Study 7983993 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.5 mg/kg infused in 5% dextrose on alternate days for 14 doses)
Number of subjects: 80
Study 7983993 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate (20 mg/kg in two divided doses daily for 40 days)
Number of subjects: 80
Study 7983993 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 80
Study 2596425 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 29001 (0.15 U/kg body wt)
Number of subjects: 12
Study 1096609 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 30
Study 1096609 — intervention group
Group type: COMPARATOR
Intervention: Control (no prostaglandin E2)
Number of subjects: 30
Study 31498467 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of absolute voice rest
Number of subjects: 30
Study 31498467 — intervention group
Group type: COMPARATOR
Intervention: No voice rest (control)
Number of subjects: 30
Study 31395035 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-for-age Z score (HAZ)
Number of subjects: 178393
Study 28918534 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical helmet systems (SHS) without tape at the gown/glove interface
Number of subjects: 75
Study 28918534 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical gowns (SG)
Number of subjects: 75
Study 28918534 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical helmet systems (SHS) with tape at the gown/glove interface
Number of subjects: 75
Study 28918534 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical helmet systems (SHS) without tape
Number of subjects: 75
Study 26405263 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 30 mg followed by DSG 75 µg per day for 20 days
Number of subjects: 71
Study 26405263 — intervention group
Group type: COMPARATOR
Intervention: UPA 30 mg followed by placebo matching DSG for 20 days
Number of subjects: 71
Study 26405263 — intervention group
Group type: COMPARATOR
Intervention: Placebo matching UPA followed by DSG 75 µg per day for 20 days
Number of subjects: 71
Study 23700090 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 60,000 U
Number of subjects: 222
Study 23700090 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) ≥30,000 U
Number of subjects: 222
Study 23700090 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EPC levels
Number of subjects: 222
Study 21786319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 107
Study 21786319 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 107
Study 21786319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise group
Number of subjects: 107
Study 21786319 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 18586990 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatments for depression, anxiety, and conduct problems in children
Number of subjects: 68
Study 16494662 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmodern ironist concept of research validity
Number of subjects: 0
Study 16494662 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmodern critique of modernist nursing research
Number of subjects: 0
Study 16494662 — intervention group
Group type: EXPERIMENTAL
Intervention: Writings of poststructuralist philosophers
Number of subjects: 0
Study 12846095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of all visible veins of the seminal cord
Number of subjects: 418
Study 12846095 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical reconstruction by connecting the distal end of the lower epigastric vein
Number of subjects: 418
Study 10690447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercise
Number of subjects: 28
Study 10690447 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 28
Study 9099449 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Lamisil (terbinafine) once daily for 15 days under fed condition
Number of subjects: 30
Study 9099449 — intervention group
Group type: COMPARATOR
Intervention: 250 mg Lamisil (terbinafine) once daily for 15 days under fasted condition
Number of subjects: 30
Study 7895357 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring and electrophysiological study
Number of subjects: 226
Study 7895357 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 226
Study 7895357 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiological study
Number of subjects: 226
Study 7895357 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of both spontaneous and inducible arrhythmias
Number of subjects: 226
Study 2706190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium octanoate
Number of subjects: 0
Study 2706190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate
Number of subjects: 0
Study 2706190 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 31455425 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous (IV) zoledronic acid (ZA) administered within 24 hours of chemotherapy, repeated every 21 days for 6 cycles.
Number of subjects: 246
Study 31455425 — intervention group
Group type: COMPARATOR
Intervention: Standard 6 cycles of neoadjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy without ZA.
Number of subjects: 246
Study 31455425 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous (IV) zoledronic acid (ZA) in postmenopausal women.
Number of subjects: 246
Study 31455425 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous (IV) zoledronic acid (ZA) in premenopausal women.
Number of subjects: 246
Study 31455425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum levels of insulin.
Number of subjects: 246
Study 28934762 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/wk of aerobic exercise (low dose)
Number of subjects: 39
Study 28934762 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min/wk of aerobic exercise (high dose)
Number of subjects: 39
Study 28934762 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 60 min/wk increase in exercise
Number of subjects: 39
Study 28934762 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 39
Study 25280197 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM) intervention
Number of subjects: 184
Study 25280197 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) intervention
Number of subjects: 184
Study 25280197 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 24553356 — intervention group
Group type: EXPERIMENTAL
Intervention: Postemployment advisory support and financial incentives (ERA program)
Number of subjects: 0
Study 24553356 — intervention group
Group type: COMPARATOR
Intervention: Control group (not eligible for ERA)
Number of subjects: 0
Study 21237568 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (40mg per 70kg) infusion
Number of subjects: 10
Study 21237568 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10